<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04874168</url>
  </required_header>
  <id_info>
    <org_study_id>tapblockvwoundInfiltration</org_study_id>
    <nct_id>NCT04874168</nct_id>
  </id_info>
  <brief_title>The Efficacy of Transversus Abdominis Plane Block Versus Wound Infiltration for Analgesia After Cesarean Delivery:</brief_title>
  <acronym>TAPBLOCK</acronym>
  <official_title>The Efficacy of Transversus Abdominis Plane Block Versus Wound Infiltration for Analgesia After Cesarean Delivery: (A Randomized Controlled Double-blinded Clinical Trial )</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aimed to compare bilateral ultrasound-guided TAP block with single-shot local&#xD;
      anesthetic wound infiltration for analgesia after cesarean delivery performed under spinal&#xD;
      anesthesia&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This double-blind, randomized controlled trial aimed to compare bilateral ultrasound-guided&#xD;
      TAP block to single-shot local anesthetic wound infiltration for analgesia after cesarean&#xD;
      delivery performed under spinal anesthesia. This will be done by measuring VAS (visual&#xD;
      analogue score) for pain after ceserian section at2, 4, 6, 12, 24 hours .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>computer-generated table of random numbers</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The degree of pain at rest ;</measure>
    <time_frame>From 2 hours to 24 hours postoperatively</time_frame>
    <description>using an Visual analogue scale (VAS) scores for pain intensity reported on 0-10 point scale for analysis. (0 = no pain and 10 = the worst possible pain) .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The time to the first postoperative opioid dose</measure>
    <time_frame>at 2, 4, 6, and 12 hours.</time_frame>
    <description>cumulative opioid consumption</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The degree of pain on movement (hip flexion and coughing)</measure>
    <time_frame>From 2 hours to 24 hours postoperatively</time_frame>
    <description>using an Visual analogue scale (VAS) scores for pain intensity reported on 0-10 point scale for analysis. (0 = no pain and 10 = the worst possible pain) .</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Cesarean Section Complications</condition>
  <arm_group>
    <arm_group_label>In the TAP group (Group A )</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>after completion of surgery, bilateral ultrasound-guided TAP block was performed .&#xD;
Description of the intervention: a 12-4-MHz linear array transducer (ClearVue 350; Philips, Bothell, WA) placed transversely between the iliac crest and costal margin in the anterior axillary line and slid medial-lateral to visualize the external oblique, internal oblique, and trans-versus abdominis muscles; the most lateral (posterior) position obtaining a satisfactory ultrasound image was used ;A 22-gauge spinal needle was introduced from medial to lateral in-plane to the ultrasound probe, and 20 mL of bupivacaine 0.25% was injected under visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>In the infiltration group (Group B )</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>at the end of surgery, 40 mL of bupivacaine 0.25% was injected subcutaneously in the surgical wound (20 mL in each of the upper and lower sides) by the obstetrician before skin closure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>In placebo group (Group C )</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>routine analgesic was administered and recorded .</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TAP block</intervention_name>
    <description>bilateral ultrasound-guided TAP block was performed using a 12-4-MHz linear array transducer (ClearVue 350; Philips, Bothell, WA) placed transversely between the iliac crest and costal margin in the anterior axillary line and slid medial-lateral to visualize the external oblique, internal oblique, and trans-versus abdominis muscles; the most lateral (posterior) position obtaining a satisfactory ultrasound image was used</description>
    <arm_group_label>In placebo group (Group C )</arm_group_label>
    <arm_group_label>In the TAP group (Group A )</arm_group_label>
    <arm_group_label>In the infiltration group (Group B )</arm_group_label>
    <other_name>wound infiltration</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women undergoing cesarean section under spinal anesthesia&#xD;
&#xD;
          -  Aged ≥19 years and &gt; 40 years .&#xD;
&#xD;
          -  Gestational age ≥ 37 Weeks .&#xD;
&#xD;
          -  Informed Consent From the Patient .&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) ≥40 kg/m2 ..&#xD;
&#xD;
          -  History of recent opioid exposure .&#xD;
&#xD;
          -  Hypersensitivity to any of the drugs used in the study .&#xD;
&#xD;
          -  Significant cardiovascular, renal, or hepatic disease.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Women undergoing cesarean section under spinal anesthesia .</gender_description>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed G Elnajar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed Gamal Elnajar, MD</last_name>
    <phone>0201092672757</phone>
    <email>a7medgamal2020.ag@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ain Shams University</name>
      <address>
        <city>Cairo</city>
        <state>Alabbasia</state>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ahmed G elnajar, md</last_name>
      <phone>0201092672757</phone>
      <email>a7medgamal2020.ag@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 25, 2021</study_first_submitted>
  <study_first_submitted_qc>May 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2021</study_first_posted>
  <last_update_submitted>May 1, 2021</last_update_submitted>
  <last_update_submitted_qc>May 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Mohamed Hassan Mohamed Mostafa</investigator_full_name>
    <investigator_title>Clinical professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

